Clinical Trial Search

Primary: Change Rate of Prostate-specific Antigen (PSA) < Nadir + 2 ng/mL From First Day of Treatment to 15 Months (Cohort 2) — 100; 100 percentage of participants

Primary: Number of Participants With Moderate to Severe UC Who Showed Clinical Remission as Defined by the MMS — 9; 17; 22 Participants

Primary: Number of Participants With Solicited Local Adverse Reactions (ARs) and Systemic ARs — 46; 68; 5; 34 Participants

Primary: Change From Baseline in the Mean NRS Score at Week 8 of the Treatment Period — -2.97; -3.65; -3.64; -2.86 points — p=0.770

Primary: Change in Oxygenation Index (OI) — -0.7; -1.5; 0.8; -1.1 cmH20/mmHg — p=0.34

Primary: Efficacy of Atezolizumab in Combination With Bevacizumab - PFS — 11.3 Months

Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants

Primary: Dose Limiting Toxicities in Part 1 and Part 1A — 0; 0; 1; 1 Participants

Primary: Number of Dose Limiting Toxicities (DLTs) — 1; 1; 0; 0 Dose limiting toxicities

Primary: Cardiac Output Reserve (Qc) — 3.3; 3.8 Liters/Min

Primary: Percentage of Patients With Disease Free Survival — 65.8 percentage of paticipants

Primary: Objective Response Rate (ORR) — 50.6 Percentage of participants

Primary: Change in Upper Extremity Motor Score (UEMS) With Manual Muscle Testing — 3.5; 2.55 score on a scale

Primary: Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE) — 13; 15; 15; 12 Participants

Primary: Total Number of Participants Enrolled in Each Appendix — 323; 320; 320 Participants